Last reviewed · How we verify

Rituximab, MTX, folic acid

Celltrion · Phase 1 active Small molecule

Rituximab, MTX, folic acid is a Small molecule drug developed by Celltrion. It is currently in Phase 1 development. Also known as: Rituximab=CT-P10.

At a glance

Generic nameRituximab, MTX, folic acid
Also known asRituximab=CT-P10
SponsorCelltrion
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rituximab, MTX, folic acid

What is Rituximab, MTX, folic acid?

Rituximab, MTX, folic acid is a Small molecule drug developed by Celltrion.

Who makes Rituximab, MTX, folic acid?

Rituximab, MTX, folic acid is developed by Celltrion (see full Celltrion pipeline at /company/celltrion).

Is Rituximab, MTX, folic acid also known as anything else?

Rituximab, MTX, folic acid is also known as Rituximab=CT-P10.

What development phase is Rituximab, MTX, folic acid in?

Rituximab, MTX, folic acid is in Phase 1.

Related